Genesis Biotechnology Group (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development (GD3) have acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS).
 
Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism and analytical chemistry services to clients worldwide.
 
“This is our second acquisition in the space of two months as we further expand our presence in the San Francisco bay area, which we see as a market with tremendous growth potential for drug discovery services,” said Eli Mordechai, Ph.D., chief executive officer of GBG. “Adding IAS’s GxP compliant bioanalytical platform to GD3’s existing portfolio would allow us to further broaden our services around PK profiling and GLP toxicology while being in close proximity to our pharma and biotech partners on the west coast.”
 
“While we continue to add complementary services to expand into new markets, we are also adding scale to increase market share with our existing services,” added Ben Bandaru, Ph.D., director of corporate development for GBG. “Acquisition of IAS provides scale for our bioanalytical capabilities in a GLP setting.”
 
“The team at IAS is honored and excited to join forces with the GD3 family of CROs. We strongly believe that our membership in the GD3 portfolio will position IAS to better serve current clients while also broadening our reach to develop new customers,” commented Jonah Michaelian, IAS’s managing director. “The acquisition by GD3 will enable IAS to realize the full potential of the analytical and regulatory infrastructure it has built over the past sixteen years and to establish itself as a center for bioanalytical excellence.”